Mycophenolate mofetil vs IV cyclophosphamide
ESKD · patients with induction therapy in lupus nephritis
It is very uncertain whether mycophenolate mofetil (MMF) changes ESKD compared with IV cyclophosphamide (CPA) (very low certainty).
1 finding from 1 review
- Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes onlyRR 0.71 [0.27, 1.84]3 studies · 231 participantsVery low